home / stock / huge / huge news

HUGE News and Press, FSD Pharma Inc. From 06/28/24

Stock Information
Company Name: FSD Pharma Inc.
Stock Symbol: HUGE
Market: NASDAQ
Website: fsdpharma.com
Menu
HUGE HUGE Quote HUGE Short HUGE News HUGE Articles HUGE Message Board
Get HUGE Alerts

News, Short Squeeze, Breakout and More Instantly...
HUGE - FSD Pharma provides Corporate Update

TORONTO, ON / ACCESSWIRE / June 28, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (" FSD Pharma " or the " Company "), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to provide the following corporate update. Corpo...
HUGE - US Companies Moving the Markets, Morning edition
Fri, Jun 28, 2024 as of 10.00 am ET

A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...

HUGE - FSD Pharma Wins $3M Final Judgment Against Dr. Raza Bokhari, Current Chairman and CEO of Medicus Pharma

2024-06-28 08:36:40 ET DENVER, Colo., Jun 28, 2024 ( 247marketnews.com )- FSD Pharma Inc. (NASDAQ: HUGE ) reported that the United States District Court for the Eastern District of Pennsylvania confirmed FSD Pharma, Inc.’s motion for entry of judgment is granted and judgment ...

HUGE - FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.

TORONTO, ON / ACCESSWIRE / June 28, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (" FSD Pharma "), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that on June 2...
HUGE - InvestorNewsBreaks - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Notes 'Important Step' as Phase 1 Lucid-21-302 Trial Receives HREC Approval

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has received a key approval for its planned Lucid-21-302 trial. According to the announcem...

HUGE - FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia

TORONTO, ON / ACCESSWIRE / June 27, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (" FSD Pharma "), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that it has re...

HUGE - InvestorNewsBreaks - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Signs Option Agreement with USC to Exclusively Evaluate Novel Technology for Commercialization

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into an exclusive option agreement with the University of Southern California (“USC”). Signed June 11, 2024, the o...
HUGE - FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business Applications

TORONTO, ON / ACCESSWIRE / June 13, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (" FSD Pharma "), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that it ente...

HUGE - InvestorNewsBreaks - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces IRB Approval for Acute Alcohol Intoxication Study

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has received approval for its METAL-2 trial to be conducted in the United States. The appr...

HUGE - FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication

TORONTO, ON / ACCESSWIRE / June 4, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (" FSD Pharma "), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today confirms that it has rece...
Previous 10 Next 10